1. SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding? 
Gary C.W. Chan, Sydney C.W. Tang 
Kidney International 
Volume 93, Issue 1, Pages (January 2018)
DOI: /j.kint
Copyright © 2017 International Society of Nephrology Terms and Conditions

2. Figure 1
Potential mechanisms at play to maintain the blood pressure (BP)–lowering effect of empagliflozin despite reducing renal function. CKD, chronic kidney disease.
Kidney International  , 22-24DOI: ( /j.kint )
Copyright © 2017 International Society of Nephrology Terms and Conditions